Magnus Financial Group LLC Invests $204,000 in Edwards Lifesciences Co. (NYSE:EW)

Magnus Financial Group LLC acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,678 shares of the medical research company’s stock, valued at approximately $204,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $34,000. Operose Advisors LLC grew its holdings in shares of Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. raised its position in Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after purchasing an additional 474 shares during the period. NBC Securities Inc. bought a new stake in Edwards Lifesciences in the third quarter worth $52,000. Finally, ORG Partners LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at about $66,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Stifel Nicolaus increased their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Friday. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Oppenheimer increased their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Finally, Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 0.6 %

NYSE:EW opened at $85.95 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm’s 50-day moving average price is $90.27 and its 200-day moving average price is $79.06. The company has a market capitalization of $51.74 billion, a PE ratio of 37.05, a P/E/G ratio of 4.28 and a beta of 1.05. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.